Developing advanced optical instrumentation using Stochastic Constellation Diffusance to give drug discovery researchers and diagnostic clinicians a new tool that is fast, accurate, and flexible.
Explore Our TechnologyCore Technology
SCD is a new optical measurement technology built on two key innovations: a new type of optical measurement over a broad heterogeneous area, and a unique approach to multiplexing the optical data. The result is single-molecule detection and weak-binding measurement capability on a platform of proven, existing technology components.
Simultaneous measurement of optical behavior across a wide imaging area enables true real-time multiplexed assays—a major advance over sequential flow cytometry approaches.
SCD enables detection at the single-molecule level, allowing researchers to observe individual protein association and dissociation events, even for weak binding interactions, on a sub-second timescale.
Built on system integration of existing proven technology components and not dependent on specialized biochemistry, SCD offers a reliable path to commercialization. Compatible with super-resolution optics.
Applications
SCD addresses ongoing needs for improved quality assurance and improved discovery & diagnostics with better speed, sensitivity, and reliability.
Cell lines face ongoing problems with intraspecies, bacterial, and mycoplasma contamination that can be burdensome to monitor. SCD enables rapid nondestructive monitoring of such contamination to de-risk subsequent development schedules and financing. AI models would keep pace with natural drift, providing continuous quality assurance without disrupting workflows.
Current technologies require time-consuming gel-bead incubation, sequential flow cytometry, and strong binding. SCD surpasses these with much higher sample throughput, added capabilities, and simpler hardware. Critically, intractable targets such as Inherently Disordered Proteins can be explored through measurement of weak binding on short time scales—providing better early data crucial to avoiding costly late-stage drug discovery failures.
Why SCD
Higher throughput than sequential flow cytometry approaches, with true parallel measurement
Weak binding detection unlocks intractable targets including Inherently Disordered Proteins
Single-molecule sensitivity for individual protein association and dissociation events in real time
Simpler hardware integrated from proven components reduces complexity and cost
Nondestructive monitoring of cell line contamination without workflow disruption
AI-integrated analysis with subscription models that keep pace with natural biological drift
Leadership
Scintimetrics brings together expertise spanning analytical chemistry, physics, drug discovery, and bioorganic chemistry.
Founder & CEO
Ph.D. in Analytical Chemistry from the University of Vermont with postdoctoral research at UCSD. Career-long prototype development leader at Northrop Grumman, General Atomics, and UCSD. Holds 22 patents in 11 countries in biotechnology. Winner of the National Instruments Overall Best Application of Virtual Instrumentation award.
Chief Technical Officer
Ph.D. in Physics from the University of Toledo and M.B.A. from the University of San Diego. IEEE Fellow with broad expertise in electromagnetism, superconductivity, cryogenics, and biomedical instrumentation. 112 scientific publications, 13 books/chapters, and 12 patents. Developed the first clinically accepted SQUID system for medical diagnostics. Member, American Society of Hematology
Chief Science Officer
Ph.D. in Chemistry from the University of Vermont. Professor Emeritus at the University of Massachusetts with over 40 years in Biochemistry and Bioorganic Chemistry. Consulting Director of Research at Associates of Cape Cod. Expertise in endotoxin and glucan detection, biosensors, and nanoscale materials.
Intellectual Property & Progress
Scintimetrics has completed physics simulations and two tiers of prototype development demonstrating clear viability, with four additional tiers planned. The company has generated interest from leading organizations in optics, instrumentation, diagnostics, and academic research.
Business Model
Commercialization will focus on three revenue streams: sale of certified consumables for use with SCD instrumentation, subscription service for periodically updated AI models, and instrument licensing. Marketing targets both academic institutions for research evaluation and pharmaceutical corporations for advancement of specific medication projects.
Interested in learning more about Stochastic Constellation Diffusance technology? We welcome inquiries from researchers, clinicians, and industry partners.
[email protected]